Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants orphan drug designation to Immunomedics' IMMU-132 for SCLC

Dec. 5, 2013

Genentech begins phase II trial of DNIB-0600A

Dec. 5, 2013

OncoMed and Celgene sign agreement for anti-cancer stem cell product candidates

Dec. 5, 2013

Alphavirus-based vaccine encoding PSA tested in mouse model of prostate cancer

Dec. 4, 2013

FDA clears California Stem Cell's application for phase III cancer stem cell trial

Dec. 4, 2013

Celldex Therapeutics initiates study of glembatumumab vedotin for triple-negative breast cancer

Dec. 4, 2013

Immunotherapeutic 3M-052 shows oncolytic potential

Dec. 3, 2013

ARMO BioSciences begins phase I study of AM-0100 in advanced solid tumors

Nov. 29, 2013

Immatics presents preliminary phase I results for the novel cancer vaccine IMA-950

Nov. 29, 2013

SillaJen to acquire Jennerex

Nov. 29, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...